Biogen Inc. (NASDAQ:BIIB) EVP Susan H. Alexander sold 4,974 shares of Biogen stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $290.01, for a total transaction of $1,442,509.74. Following the transaction, the executive vice president now directly owns 22,258 shares of the company’s stock, valued at $6,455,042.58. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of Biogen Inc. (NASDAQ BIIB) traded down 2.81% during trading on Thursday, reaching $287.29. 1,156,714 shares of the company’s stock were exchanged. The stock has a 50-day moving average price of $272.62 and a 200 day moving average price of $273.66. Biogen Inc. has a 12-month low of $244.28 and a 12-month high of $307.76. The company has a market capitalization of $60.94 billion, a P/E ratio of 17.99 and a beta of 0.78.

Biogen (NASDAQ:BIIB) last issued its earnings results on Tuesday, July 25th. The biotechnology company reported $5.04 earnings per share for the quarter, topping the consensus estimate of $4.36 by $0.68. Biogen had a return on equity of 37.42% and a net margin of 28.10%. The business had revenue of $3.08 billion for the quarter, compared to analyst estimates of $2.81 billion. During the same quarter last year, the company earned $5.21 EPS. The business’s quarterly revenue was up 6.4% on a year-over-year basis. Equities analysts expect that Biogen Inc. will post $21.33 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Biogen Inc. (NASDAQ:BIIB) EVP Sells $1,442,509.74 in Stock” was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The original version of this report can be read at https://www.dailypolitical.com/2017/07/27/biogen-inc-nasdaqbiib-evp-sells-1442509-74-in-stock.html.

Large investors have recently modified their holdings of the company. Janney Montgomery Scott LLC raised its stake in shares of Biogen by 7.9% in the second quarter. Janney Montgomery Scott LLC now owns 36,502 shares of the biotechnology company’s stock valued at $9,905,000 after buying an additional 2,673 shares during the period. Taylor Cottrill Erickson & Associates Inc. raised its stake in shares of Biogen by 3.1% in the second quarter. Taylor Cottrill Erickson & Associates Inc. now owns 992 shares of the biotechnology company’s stock valued at $269,000 after buying an additional 30 shares during the period. Harbour Capital Advisors LLC raised its stake in shares of Biogen by 18,428.2% in the second quarter. Harbour Capital Advisors LLC now owns 233,641 shares of the biotechnology company’s stock valued at $861,000 after buying an additional 232,380 shares during the period. IBM Retirement Fund raised its stake in shares of Biogen by 112.4% in the second quarter. IBM Retirement Fund now owns 5,190 shares of the biotechnology company’s stock valued at $1,574,000 after buying an additional 2,746 shares during the period. Finally, NGAM Advisors L.P. raised its stake in shares of Biogen by 3.0% in the second quarter. NGAM Advisors L.P. now owns 60,577 shares of the biotechnology company’s stock valued at $16,438,000 after buying an additional 1,765 shares during the period. 87.50% of the stock is currently owned by institutional investors and hedge funds.

Several research firms have commented on BIIB. UBS AG reaffirmed a “neutral” rating and set a $285.00 price objective (up from $270.00) on shares of Biogen in a research note on Wednesday. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Biogen in a research note on Thursday, May 25th. Vetr lowered shares of Biogen from a “strong-buy” rating to a “buy” rating and set a $311.67 price objective for the company. in a research note on Wednesday, June 21st. Deutsche Bank AG reaffirmed a “buy” rating and set a $319.00 price objective (up from $315.00) on shares of Biogen in a research note on Wednesday. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Biogen in a research note on Wednesday, March 29th. Fourteen analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Biogen currently has an average rating of “Buy” and an average price target of $327.16.

Biogen Company Profile

Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).

Insider Buying and Selling by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.